Trials / Completed
CompletedNCT04088929
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Pure Green · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBD | A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes. |
Timeline
- Start date
- 2019-09-30
- Primary completion
- 2019-11-22
- Completion
- 2019-12-01
- First posted
- 2019-09-13
- Last updated
- 2019-12-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04088929. Inclusion in this directory is not an endorsement.